advertisement
11.3.3 Apraclonidine, brimonidine (9)
Showing records 1 to 9
Display all abstracts in classification 11.3.3 Apraclonidine, brimonidine
Search within classification 11.3.3 Apraclonidine, brimonidine6169 Effect of brimonidine on rabbit trabecular meshwork hyaluronidase activity
Benozzi J; Jaliffa CO; Firpo Lacoste F; Llomovatte DW; Keller Sarmiento MI; Rosenstein RE
Investigative Ophthalmology and Visual Science 2000; 41: 2268-2272
6170 Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: a randomized clinical trial
Javitt JC; Schiffman RH
Journal of Glaucoma 2000; 9: 224-234
6171 A case of suspected Alphagan-induced psychosis
Kim DD; Bay G
American Journal of Ophthalmology 2000; 8: 1132-1133
6172 The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty
Ma YR; Lee BH; Yang KJ; Park YG
Korean Journal of Ophthalmology 1999; 13: 78-84
6173 Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol: Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology 2000; 107: 1171-1177
6174 Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma: ALPHAGAN/XALATAN Study Group
Simmons ST; Samuelson TW
Clinical Therapeutics 2000; 22: 388-399
6175 Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
Journal of Ocular Pharmacology and Therapeutics 2000; 16: 251-259
6176 Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure
Stewart WC; Sharpe ED; Harbin TS Jr; Pastor SA; Day DG; Holmes KT; Stewart JA
American Journal of Ophthalmology 2000; 129: 723-727
6177 Incidence of brimonidine allergy in patients previously allergic to apraclonidine
Williams GC; Orengo-Nania S; Gross RL
Journal of Glaucoma 2000; 9: 235-238